TABLE 2.
Baseline Sample Characteristics by Treatment Arm
| SRP, n = 191 |
UC, n = 190 |
Total, n = 381 |
|
|---|---|---|---|
| Characteristic | Mean (SD)/No. (%) | Mean (SD)/No. (%) | Mean (SD)/No. (%) |
| Femalea | 99 (51.8%) | 99 (52.1%) | 198 (52.0%) |
| Age, ya | 55.0 (11.0) | 55.2 (10.6) | 55.0 (10.8) |
| Race | |||
| White | 181 (95.3%) | 171 (90.0%) | 352 (92.6%) |
| Black/African American | 3 (1.6%) | 10 (5.3%) | 13 (3.4%) |
| Other | 6 (3.2%) | 9 (4.7%) | 15 (3.9%) |
| Hispanic ethnicity | 13 (7.0%) | 13 (7.2%) | 26 (7.1%) |
| White, non-Hispanica | 173 (90.6%) | 162 (85.3%) | 335 (87.9%) |
| Married/living togethera | 107 (56.0%) | 101 (53.2%) | 208 (54.6%) |
| Education >High schoola | 99 (52.7%) | 102 (55.4%) | 201 (54.0%) |
| Income >$30,000/ya | 104 (57.1%) | 97 (55.8%) | 201 (57.0%) |
| Employeda | 112 (60.2%) | 101 (54.6%) | 213 (57.4%) |
| Cancer site | |||
| Thoracic | 40 (20.9%) | 33 (17.4%) | 73 (19.2%) |
| Head and neck | 36 (18.8%) | 35 (18.4%) | 71 (18.6%) |
| Gastrointestinal | 24 (12.6%) | 30 (15.8%) | 54 (14.2%) |
| Breast | 22 (11.5%) | 26 (13.7%) | 48 (12.6%) |
| Genitourinary | 24 (12.6%) | 15 (7.9%) | 39 (10.2%) |
| Gynecological | 19 (9.9%) | 14 (7.4%) | 33 (8.7%) |
| Hematological | 13 (6.8%) | 24 (12.6%) | 37 (9.7%) |
| Cutaneous | 9 (4.7%) | 8 (4.7%) | 17 (4.5%) |
| Other | 4 (2.1%) | 5 (2.6%) | 9 (2.4%) |
| TNM disease stage | |||
| Unstaged | 15 (7.9%) | 32 (16.8%) | 47 (12.3%) |
| Stage 0 | 7 (3.7%) | 2 (1.1%) | 9 (2.4%) |
| Early (stage I-II) | 111 (58.1%) | 87 (45.8%) | 198 (52.0%) |
| Late (stage III-IV) | 58 (30.4%) | 69 (36.3%) | 127 (33.3%) |
| ECOG rating | |||
| Fully active | 98 (51.3%) | 93 (49.0%) | 191 (50.1%) |
| Restricted | 61 (31.9%) | 71 (37.3%) | 132 (34.7%) |
| Ambulatory | 12 (6.3%) | 12 (6.3%) | 24 (6.3%) |
| Limited | 0 (0.0%) | 3 (1.6%) | 3 (0.8%) |
| Not applicable | 20 (10.5%) | 11 (5.8%) | 31 (8.1%) |
| Brief Pain Inventory: severity (0-40) | 14.6 (10.0) | 16.2 (10.7) | 15.3 (10.4) |
| Brief Fatigue Inventory: severity (0-30) | 15.5 (8.7) | 16.3 (8.7) | 15.9 (8.7) |
| Has a comorbidity | 70 (36.7%) | 68 (35.8%) | 138 (36.2%) |
| No. of cigarettes/d | 21.6 (9.5) | 19.7 (9.1) | 20.6 (9.3) |
| No. of y smoking | 35.0 (12.5) | 34.3 (11.7) | 34.6 (12.1) |
| Fagerström Test for Nicotine | 5.3 (2.1) | 5.0 (2.2) | 5.2 (2.1) |
| Dependencea | |||
| Quit smoking when diagnoseda | 89 (48.6%) | 93 (50.3%) | 182 (49.5%) |
| 7-d point prevalent abstinenta | 134 (70.2%) | 128 (67.4%) | 262 (68.8%) |
| Using pharmacotherapy as a quit aid | 58 (30.4%) | 60 (31.6%) | 118 (31.0%) |
| Extremely confident abstinent in 6 moa | 91 (48.4%) | 106 (56.7%) | 197 (52.5%) |
| Quitting self-efficacy (9-45)a | 38.0 (7.6) | 38.3 (7.6) | 38.2 (7.6) |
| Fears about cancer (4-20) | 9.7 (3.8) | 10.3 (3.8) | 10.0 (3.8) |
| Perceived risk of cancer recurrence (7-28) | 22.9 (4.3) | 22.5 (4.4) | 22.7 (4.3) |
| Depression (8-32) | 15.9 (5.9) | 16.8 (5.9) | 16.3 (5.9) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; SRP, smoking relapse prevention; UC, usual care.
There were no statistically significant differences noted between the groups.
Values were based on available responses; some items were not completed by all patients.
a
Variable was evaluated as a prospective moderator; the variable and its interaction with the condition were included in the multiple imputation model.